Rigel Pharmaceuticals, Inc. - Common Stock (RIGL)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 14, 2026Investment Snapshot
- Trading 40% below Graham Number ($53.18) — significant margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 26.9% with 38.0% net margin
- Revenue growing at 64% annually
Rigel Pharmaceuticals, Inc. - Common Stock (RIGL) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $594 million . Key value metrics: P/E ratio 5.5, P/B ratio 1.49, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Rigel Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
Rigel Pharmaceuticals, Inc. - Common Stock (RIGL) is trading 40% below its Graham Number of $53.18 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 5.5x.
On financial health, RIGL shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 26.9% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.11.
StockPik's composite Value Score for RIGL is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RIGL reports a high gross margin of 93.6% (sector average: 40.1%) and a strong operating margin of 40.3%.
RIGL shows revenue growing at 64% year-over-year, with earnings growing at 1,999%.